Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Genmab A/S    GMAB   DK0010272202

GENMAB A/S

(GMAB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
10/20/2020 10/21/2020 10/22/2020 10/23/2020 10/26/2020 Date
2260(c) 2228(c) 2208(c) 2210(c) 2195 Last
154 245 184 648 159 235 111 405 153 447 Volume
-1.99% -1.42% -0.90% +0.09% -0.68% Change
More quotes
Financials
Sales 2020 9 610 M 1 531 M 1 531 M
Net income 2020 4 651 M 741 M 741 M
Net cash position 2020 13 484 M 2 149 M 2 149 M
P/E ratio 2020 30,5x
Yield 2020 -
Sales 2021 7 791 M 1 241 M 1 241 M
Net income 2021 2 625 M 418 M 418 M
Net cash position 2021 16 178 M 2 578 M 2 578 M
P/E ratio 2021 52,6x
Yield 2021 -
Capitalization 144 B 22 988 M 23 016 M
EV / Sales 2020 13,6x
EV / Sales 2021 16,5x
Nbr of Employees 636
Free-Float 95,2%
More Financials
Company
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (58.8%); - income from research and development (34.8%); - other (6.4%): primarily income from partnership agreement. At the end of 2019, the group had a portfolio of 18 products in... 
Sector
Biotechnology & Medical Research
Calendar
11/04 | 12:00pmEarnings Release
More about the company
Notations Surperformance© of Genmab A/S
Trading Rating : Investor Rating :
More Ratings
All news about GENMAB A/S
10/22GENMAB A/S : Announces IFM, HOVON and Janssen Achieve Positive Topline Results i..
AQ
10/21GENMAB A/S : Announces IFM, HOVON and Janssen Achieve Positive Topline Results i..
AQ
10/21GENMAB A/S : Announces IFM, HOVON and Janssen Achieve Positive Topline Results i..
AQ
10/21Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in S..
GL
10/16GENMAB A/S : has published its Articles of Association
AQ
10/16NOVARTIS : Genmab to Host Capital Markets Day
AQ
10/15GENMAB A/S : Articles of association dated October 07, 2020 – English
PU
10/15GENMAB A/S : has published its Articles of Association
PU
10/15GENMAB A/S : to Host Capital Markets Day
AQ
10/15BioNTech to Present Data from BNT311 and BNT131 Programs at SITC 35th Annual ..
AQ
10/15Genmab Announces Data to be presented at SITC 35th Anniversary Annual Meeting
AQ
10/14GENMAB A/S : Announces Data to be Presented at SITC 35th Anniversary Annual Meet..
AQ
10/14GENMAB A/S : Announces Net Sales of DARZALEX for Third Quarter of 2020
AQ
10/13GENMAB A/S : Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of..
AQ
10/13GENMAB A/S : Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of..
AQ
More news
News in other languages on GENMAB A/S
10/22GENMAB : résultats d'un médicament contre le cancer
10/2120 valeurs de croissance cotées en Europe
09/25TOUR DU MONDE DES INDICES :  Tesla-dépendance et irréductibles danois
09/23GENMAB : procédure d'arbitrage à l'encontre de Janssen
09/21TOUR DU MONDE DES INDICES : Les secteurs sont à l’honneur
More news
Stock Trading Strategies
GENMAB A/S - 06/15
The underlying trend is to the upside
BUY
More Stock Trading Analysis
Chart GENMAB A/S
Duration : Period :
Genmab A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENMAB A/S
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 2 093,01 DKK
Last Close Price 2 210,00 DKK
Spread / Highest target 26,7%
Spread / Average Target -5,29%
Spread / Lowest Target -89,7%
EPS Revisions
Managers
NameTitle
Jan G. J. van de Winkel President & Chief Executive Officer
Deirdre P. Connelly Chairman
Anthony Mancini Chief Operating Officer & Executive Vice President
Anthony Pagano Chief Financial Officer & Executive Vice President
Michael K. Bauer SVP, Head-Operations, Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB A/S49.17%22 988
GILEAD SCIENCES, INC.-6.45%76 214
REGENERON PHARMACEUTICALS54.42%61 014
VERTEX PHARMACEUTICALS-3.37%55 110
WUXI APPTEC CO., LTD.58.33%37 775
BEIGENE, LTD.80.38%27 097